Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) EPS (diluted)
Vertex Pharmaceuticals Incorporated's EPS (diluted) for fiscal 2025 was $15.32, compared with −$2.08 in fiscal 2024. Over the twelve months to 30 June 2026 it was $17.18. Over the past ten years it has ranged from −$2.31 (fiscal 2015) to $15.32 (fiscal 2025) — the current reading is the highest in ten years. Vertex Pharmaceuticals Incorporated ranks 20th of 587 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $15.32 | — |
| FY2024 | −$2.08 | — |
| FY2023 | $13.89 | 8.35% |
| FY2022 | $12.82 | 42.29% |
| FY2021 | $9.01 | (12.44%) |
| FY2020 | $10.29 | 128.16% |
| FY2019 | $4.51 | (44.25%) |
| FY2018 | $8.09 | 677.88% |
| FY2017 | $1.04 | — |
| FY2016 | −$0.46 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $4.31 | 7.21% |
| Mar 2026 | $4.02 | (13.55%) |
| Dec 2025 | $4.65 | 10.71% |
| Sep 2025 | $4.20 | 5.26% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $40.46 |
| ARGX argenex SE compare | $26.04 |
| VRTX Vertex Pharmaceuticals Incorporated | $17.18 |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.76 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| RPRX Royalty Pharma PLC compare | $1.45 |
| ROIV Roivant Sciences Ltd. compare | −$0.29 |
| MRNA Moderna, Inc. compare | −$7.99 |
| RVMD Revolution Medicines, Inc. compare | −$8.82 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement